According to a study published in Nature Communications, enzymes that are used by bacteria to break down mucus in the gut can potentially be useful biomarkers for intestinal diseases.
Scientists succeeded in reviving microbes retrieved from sediment deep under the seafloor in the heart of the South Pacific that had survived in a dormant state for 101.5 million years in research illustrating the resiliency of life on Earth.
Rebecca Vaught never set out to become an entrepreneur, but that’s exactly what happened when she launched Van Heron Labs during 2020 with a goal of reframing the understanding of the body’s organismal and cellular performance.
Atox Bio had positive results in the company’s Phase III ACCUTE trial for reltecimod for early treatment of severe Necrotizing Soft Tissue Infection (NSTI), a so-called flesh-eating disease.
Researchers at the The Scripps Research Institute found that the strains spreading so quickly in Europe and the U.S. have a mutated S “spike” protein that makes it about 10 times more infectious than the strain that originally was identified in Asia.
A review of some recently published scientific studies includes one for antihistamines and similar compounds that might slow down Huntington’s disease.
A new weapon in the war on coronavirus is on the way. Leading health creative agency The Bloc developed SafeCode, a unique device concept which fuses a barcode scanner with UV-C light technology proven to destroy dangerous viruses and bacteria, and is expected to do the same to SARS-CoV-2, the virus that causes the novel coronavirus (COVID-19).
Pharma companies from across the globe provide updates on their pipelines and business.
Melinta Therapeutics filed for bankruptcy protection, becoming the latest casualty of a persistent cash burn in the antibiotic industry.
The U.S. Food and Drug Administration’s Antimicrobial Drugs Advisory Committee voted to recommend approval of Shionogi & Co. Ltd.’s investigational antibiotic cefiderocol for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, in patients with limited or no alternative treatment options.